KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Assets Average (2016 - 2025)

Historic Assets Average for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $3.6 billion.

  • Sarepta Therapeutics' Assets Average rose 212.21% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 212.21%. This contributed to the annual value of $3.6 billion for FY2024, which is 1305.83% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Assets Average stood at $3.6 billion for Q3 2025, which was up 212.21% from $3.6 billion recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Assets Average ranged from a high of $3.8 billion in Q4 2024 and a low of $2.7 billion during Q3 2021
  • Its 5-year average for Assets Average is $3.2 billion, with a median of $3.1 billion in 2023.
  • Within the past 5 years, the most significant YoY rise in Sarepta Therapeutics' Assets Average was 2053.87% (2021), while the steepest drop was 525.05% (2021).
  • Over the past 5 years, Sarepta Therapeutics' Assets Average (Quarter) stood at $2.9 billion in 2021, then increased by 8.16% to $3.1 billion in 2022, then rose by 1.43% to $3.2 billion in 2023, then increased by 18.65% to $3.8 billion in 2024, then dropped by 5.15% to $3.6 billion in 2025.
  • Its Assets Average was $3.6 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $3.7 billion in Q1 2025.